Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin in Hemorrhagic Shock (ABSOLUTE)
NCT06111261Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised, single-blind trial of albumin (human) in hemorrhagic shock (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Total fluid balance until physical hemostasis of bleeding is confirmed up to 48 hours. Status: unknown.
02
Drugs
albumin (human)
03
Conditions
hemorrhagic shock
Beyond the preview
Go deeper on NCT06111261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111261.